YAMAHA-MOTOR
7.8.2024 09:46:32 CEST | Business Wire | Press release
Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the first half of fiscal 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807405321/en/
Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire)
From HIDAKA, Yoshihiro
President, Chief Executive Officer and Representative Director
In the first half of fiscal 2024, we were able to set new records for revenue and incomes for the second year running. In our core business of motorcycles, increased sales of premium models in emerging markets and other factors led to us posting higher revenues and profits.
In terms of the external business environment, high prices and interest rates are affecting demand levels, and as anticipations of interest rate cuts rise in the United States, sharp fluctuations in foreign exchange rates and other developments have made things uncertain. Also, while things vary by business segment, we expect the fierce competitive environment to continue due to product supply improvements by us as well as our competitors, declining levels of demand, and other effects. Ocean freight rates are trending upward while raw material costs are generally in line with forecasts, excluding the effects of foreign exchange rates.
As for our businesses, we expect the motorcycle business to continue performing well, but for recreational vehicles and Smart Power Vehicles, inventory adjustments to lead to prolonged production cutbacks. In the Marine Products business, the new large outboard motor models we launched this season continue to receive ample customer inquiries, but we still expect demand to decline, mainly in Europe and the United States. We will continue to work toward inventory optimization, including making production adjustments that take demand levels and sales conditions into account. As for the Robotics business, we expect to see a recovery in demand in the second half of the year.
To strengthen profitability, we will be resolute in controlling expenses, improving production efficiency, and carrying out our premium segment strategy while enacting structural improvements for businesses incurring losses.
Consolidated Business Results
Revenues for the period were 1,348.4 billion yen (an increase of 122.0 billion yen or 10.0% compared with the same period of the previous fiscal year) and operating income was 154.4 billion yen (an increase of 12.9 billion yen or 9.1%). Interim net income attributable to owners of parent was 113.1 billion yen (an increase of 9.8 billion yen or 9.5%).
For the first half-year consolidated accounting period, the U.S. dollar traded at 152 yen (a depreciation of 17 yen from the same period of the previous fiscal year) and the euro at 165 yen (a depreciation of 19 yen).
In the Company’s core business of motorcycles, Brazil and India saw higher overall unit sales and higher prices per unit, which increased revenues. For operating income, the effects of higher revenue in the motorcycle business and cost-cutting efforts were compounded by the positives of a weaker yen, and this led to higher profits for the period.
*From this fiscal year, the Yamaha Motor group has switched from Japanese Generally Accepted Accounting Principles (J-GAAP) to International Financial Reporting Standards (IFRS), and as such, figures from fiscal 2023 have been converted to IFRS standards for comparison and analysis.
Results by Business Segment
Land Mobility Business
Revenues were 896.1 billion yen (an increase of 98.6 billion yen or 12.4% compared with the same period of the previous fiscal year) and operating income was 90.7 billion yen (an increase of 22.8 billion yen or 33.6%).
For the motorcycle business, unit sales rose in developed markets like Europe and the United States, resulting in higher numbers than last year. Demand in emerging markets—primarily Brazil, India, and Indonesia—went up and accordingly increased the unit sales recorded for the entire emerging market motorcycle business. Revenues for the motorcycle business went up thanks to the higher unit sales in Brazil and India as well as higher prices per unit. For operating income, in addition to the effects of higher revenues, improved supply of premium segment models in emerging markets, cost reductions, and the benefits of a weaker yen brought in higher profits.
With recreational vehicles (all-terrain vehicles and ROVs), demand has fallen below last year’s while unit sales remain roughly the same, but a worsening model mix resulted in lower sales. In addition to the higher marketing, promotional, and manufacturing expenses accompanying the intensifying competition left the business with lower profits.
For the Smart Power Vehicles business, i.e., electric wheelchairs, electrically power-assisted bicycles (eBikes) and their drive units (e-Kits), unit sales of eBikes in Japan surpassed last year’s numbers. However, in Europe, the main market for Yamaha Motor e-Kits, market inventory adjustments have remained ongoing and this led to a decline in unit sales and lower sales overall. In terms of operating income, the lower unit sales and increase in sales promotion expenses left the SPV business posting lower profits.
Marine Products Business
Revenues were 297.7 billion yen (a decrease of 1.3 billion yen or 0.4% compared with the same period of the previous fiscal year) and operating income was 53.2 billion yen (a decrease of 12.6 billion yen or 19.2%).
Outboard motor demand in Central and South America continued to be strong, but in North America and Europe, rising prices and interest rates led to a decline in demand. However, demand for large horsepower outboards in North America remained stable. Unit sales of new outboard models were positive, but sales were lower for the outboard business overall. For personal watercraft, unease about rising interest rates made customers hesitate to purchase and demand decreased, but unit sales increased thanks to improvements addressing last year’s lack of parts and supply chain disruptions, which had forced the Company to place limits on product supply. As a result, sales and profits fell for the Marine Products business overall. Also, Yamaha Motor’s half-year consolidated business results include the performance recorded by German electric marine propulsion manufacturer Torqeedo GmbH during its second quarter consolidated accounting period (April–June 2024).
Robotics Business
Revenues were 45.9 billion yen (a decrease of 0.4 billion yen or 0.8% compared with the same period of the previous fiscal year) with an operating loss of 0.4 billion yen (compared to an operating income of 5 billion yen).
In the surface mounter market, lower demand for capital investment in Europe accordingly brought down unit sales. With industrial robots, demand remained stagnant in China and sales decreased. Also, higher demand for generative AI applications and advanced packaging yielded higher sales of Yamaha semiconductor back-end process manufacturing equipment. As a result of all these developments, the Robotics business as a whole took in lower sales and its operating income for the period also fell.
Financial Services Business
Revenues were 55.9 billion yen (an increase of 17.4 billion yen or 45.3% compared with the same period of the previous fiscal year) and operating income was 10.8 billion yen (an increase of 4.2 billion yen or 63.2%).
As financial receivables increased, we made progress in passing procurement interest rates on to customers and this pushed revenues up. As for operating income, in addition to higher income from interest payments, the appraised losses derived from interest rate swaps last fiscal year were converted to appraisal gains this fiscal year. This upped profits for the period.
Other Products Business
Revenues were 52.9 billion yen (an increase of 7.7 billion yen or 17.1% compared with the same period of the previous fiscal year) and operating income was 3.6 billion yen (compared to an operating income of 0.6 billion yen).
Higher demand for golf cars in North America was behind the rise in unit sales and resulting greater revenue brought the business both increased sales and profits.
Forecast of Consolidated Business Results
Regarding the forecast consolidated business results for the fiscal year ending December 31, 2024, no changes have been made to the forecast made on February 14 when announcing the Company’s fiscal 2023 results (including the assumed foreign exchange rates):
Revenue: 2,600.0 billion yen
Operating Income: 260.0 billion yen
Net Income: 175.0 billion yen
Basic Policy Concerning Profit Distribution and Dividends for the Current Fiscal Year
For shareholder returns, the Company’s basic policy is to emphasize making consistent and ongoing dividend payments while taking into consideration the outlook for business performance and investments for future growth, distributing returns to shareholders in a flexible way based on the scale of our cash flows with the total payout ratio set at the 40% range for the cumulative total of the Medium-Term Management Plan’s three-year period.
Regarding dividends for the period, based on there being no changes to the original forecast consolidated business results for the fiscal year ending December 31, 2024, the Company resolved to keep the forecast annual dividend at 50 yen per share and the interim dividend at 25 yen per share.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807405321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
